Serum C-Reactive Protein (CRP), Target for Therapy or Trouble?
High sensitivity serum C-reactive protein (hs-CRP) has come into clinical use as a marker of risk for cardiovascular disease (CVD). In addition to a role as a marker of disease, CRP has also been implicated in the pathogenesis of CVD. Specific small-molecule inhibitors of CRP have recently been developed with the intent of mitigating cardiac damage during acute myocardial infarction. However, the use of CRP, both as a risk marker and a disease target are controversial for several reasons. Serum hs-CRP concentrations can be elevated on the basis of genetics, female gender, and non-Caucasian ethnicity. It is not clear, in these contexts, that elevations of hs-CRP have any pathological significance. As a non-specific indicator of inflammation, CRP is also not a specific indicator of a single disease state such as cardiovascular disease but elevated concentrations can be seen in association with other comorbidities including obesity and pulmonary disease. In sharp contrast to the proposed inhibition of CRP for cardiovascular disease treatment, the infusion of CRP has been shown to have profound therapeutic benefits for autoimmune disease and septic shock. The balance between the risks and benefits of these competing views of the role of CRP in disease and disease therapy is reminiscent of the ongoing controversy regarding the use of non-steroidal anti-inflammatory drugs (NSAIDs) for musculoskeletal disease and their cardiovascular side effects. Soon, NSAIDs may not be the only agents about which Rheumatologists and Cardiologists may spar.
Kraus
Virginia B
VB
Duke University Medical Center, Durham, NC 27710.
Jordan
Joanne M
JM
Am Heart J. 2006 Oct;152(4):793-800
16996860
Int Immunopharmacol. 2001 Mar;1(3):433-43
11367528
J Mol Biol. 2002 Feb 22;316(3):583-97
11866519
Am Heart J. 2004 Jul;148(1 Suppl):S19-26
15211329
J Biol Chem. 1991 Feb 5;266(4):2167-71
1989977
J Exp Med. 1981 Nov 1;154(5):1703-8
7299351
Eur Heart J. 2004 Dec;25(23):2109-19
15571826
Can J Cardiol. 2004 Aug;20 Suppl B:29B-31B
15309202
Osteoarthritis Cartilage. 2007 Aug;15(8):966-71
17395501
Clin Chim Acta. 2005 Jun;356(1-2):1-8
15936299
Genes Immun. 2002 Feb;3(1):14-9
11857055
J Biol Chem. 2004 Nov 19;279(47):48487-90
15337754
J Immunol. 2000 Jul 15;165(2):1030-5
10878380
Circulation. 1998 May 12;97(18):1837-47
9603539
Arthritis Rheum. 2005 Feb;52(2):378-81
15692995
Dev Comp Immunol. 2001 Oct-Dec;25(8-9):651-82
11602189
Circ Res. 2005 Apr 15;96(7):714-6
15774855
Nature. 2006 Apr 27;440(7088):1217-21
16642000
Microbes Infect. 2002 Feb;4(2):201-5
11880053
Clin Chem. 2004 Oct;50(10):1733-5
15388655
Clin Diagn Lab Immunol. 2003 Jul;10(4):652-7
12853400
Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1509-15
15205215
Mol Immunol. 2001 Aug;38(2-3):189-97
11532280
Am Heart J. 2005 Jun;149(6):977-83
15976778
Clin Chem. 2001 Mar;47(3):426-30
11238292
Eur J Immunol. 2003 Apr;33(4):962-9
12672062
Curr Opin Cardiol. 2005 Sep;20(5):407-16
16093760
Circulation. 2006 Jan 3;113(1):38-43
16380546
Nutr Rev. 2005 Jan;63(1):22-8
15730232
Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1091-4
15923540
J Clin Invest. 2003 Jun;111(12):1805-12
12813013
Hum Mol Genet. 2004 Jan 1;13(1):137-47
14645206
J Hypertens. 2003 Oct;21(10):1787-803
14508181
Circulation. 2003 Jan 28;107(3):499-511
12551878
J Am Coll Cardiol. 2005 Aug 2;46(3):464-9
16053959
Immunol Res. 2004;30(3):261-77
15531769
Arthritis Rheum. 2005 Jan;52(1):105-11
15641044
Immunol Res. 2001;24(2):163-76
11594454
Circ Res. 2005 Nov 25;97(11):e97-103
16254214
Atherosclerosis. 2005 Jan;178(1):139-45
15585211
Arthritis Rheum. 2005 Feb;52(2):642-50
15692982